Micro Glucagon During Exercise in Type 1 Diabetes

• Status: Not yet recruiting
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This proof-of-principle study to assess effects of different doses (mini and micro) of subcutaneous glucagon analog Dasiglucagon (Zealand Pharma, Copenhagen, Denmark) on the change in blood glucose concentration during moderate-intensity exercise in people with T1D.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Inselspital, Berne
• Treatments: Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• T1D for >1 year

• Male aged 18-45 years old

• HbA1c <8.0% (64 mmol/mol) based on analysis from the central laboratory unit of Bern University Hospital

• Regular physical activity (defined as meeting 150 min moderate-intensity exercise per week)

• Using either continuous subcutaneous insulin infusion or multiple daily injections

• Written informed consent

Exclusion Criteria:

• Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the results as judged by the investigator

• Current treatment with drugs known to interfere with metabolism e.g. systemic corticosteroids, statins, SGLT2 inhibitors, GLP1 agonists

• Relevant diabetic complications as judged by the investigator

• Body mass index 30 kg/m2

• Uncontrolled hypertension (>180/100 mmHg)